The latest attempt to spotlight Gilead Sciences (GILD) and its business practices shifted on Thursday to Congress, where a sometimes contentious hearing was held to explore the cost of an HIV prevention pill the company sells and the role the federal government played in discovering the pricey medicine.

The three-hour session was punctuated by a mix of bipartisan sparring that, at times, addressed the larger issue of patients versus profits as much as the Gilead pill, which is called Truvada and has been the focus of intense controversy in recent weeks. The hearing was pushed by AIDS activists, who also filed a lawsuit this week accusing Gilead of anti-competitive behavior to profit off its HIV pill.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy